Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Caitriona M. O' Driscoll"'
Autor:
Raphael Darcy, Jianfeng Guo, Irene Mencía Castaño, Fergal J. O’ Brien, Rosanne M. Raftery, Caitriona M. O’ Driscoll, Caroline M. Curtin, Matt Gooding, Kathleen A. Fitzgerald
Publikováno v:
International Journal of Pharmaceutics. 511:1058-1069
siRNA has emerged as a potential therapeutic for the treatment of prostate cancer but effective delivery remains a major barrier to its clinical application. This study aimed to develop and characterise a 3D in vitro co-culture model to simulate pros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70f58cd5431a61ce3558672f1b2ccf9e
https://doi.org/10.1016/j.ijpharm.2016.07.079
https://doi.org/10.1016/j.ijpharm.2016.07.079
Publikováno v:
Biomaterials. 33:7775-7784
A hepta-guanidino-β-cyclodextrin (G-CD), its hepta-PEG conjugate (G-CD-PEG), and the corresponding anisamide-terminated PEG conjugate (G-CD-PEG-AA) have been synthesised and compared as delivery vectors for siRNA to prostate cancer cells and tumours
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d27b71d052c3213f795121ce5af0df6
https://doi.org/10.1016/j.biomaterials.2012.07.012
https://doi.org/10.1016/j.biomaterials.2012.07.012
Publikováno v:
International Journal of Pharmaceutics. 413:174-183
Oral delivery of gene therapeutics would facilitate treatment of local intestinal disease, including colon cancer and inflammatory bowel disease, thus avoiding invasive surgery. The aims of this study were to investigate; if the orientation of the li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::452345cc59823c2b57e7447b45e01956
https://doi.org/10.1016/j.ijpharm.2011.04.021
https://doi.org/10.1016/j.ijpharm.2011.04.021
Autor:
Caitriona M. O’ Driscoll, Fergal J. O’ Brien, Caroline M. Curtin, Meenakshi Malhotra, Kathleen A. Fitzgerald
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 215
The development of safe, effective and patient-acceptable drug products is an expensive and lengthy process and the risk of failure at different stages of the development life-cycle is high. Improved biopharmaceutical tools which are robust, easy to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::865e6bfeacb2d2978cf4d039e4636865
https://pubmed.ncbi.nlm.nih.gov/26220617
https://pubmed.ncbi.nlm.nih.gov/26220617